Stemline Therapeutics, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Stemline Therapeutics, Inc.
- Company name
- Stemline Therapeutics, Inc.
- Organisation type
- Industry
- Registered legal name
- STEMLINE THERAPEUTICS, INC.
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 529900EFNCIRC8Q7V234
Related records
Trials (35)
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
- A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
- A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
- A Registry-study of ELZONRIS in Participants With BPDCN
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
- Circulating Tumor DNA
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Ph 2 Elacestrant in ER Positive Uterine Sarcomas
- Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer